Cartesian Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.8 | $38.9 | $26.0 | $110.8 | $85.1 |
| Operating income | -$143.4 | -$43.9 | -$86.4 | $14.5 | -$4.6 |
| Net income | -$130.3 | -$77.4 | -$219.7 | $35.4 | -$25.7 |
| Cash Flow Statement | |||||
| Free cash flow | -$79.4 | -$32.8 | -$51.4 | -$32.8 | -$61.5 |
| Dividends | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Shares outstanding 30.3M · Free float 7.1%
Annual filing data through FY ended December 31, 2025; float as of September 10, 2026.